VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
Rhea-AI Summary
VivoSim (Nasdaq: VIVS) reported that it has received a $5 million milestone payment from Eli Lilly tied to the first patient dosing in Eli Lilly’s Phase 2 studies of an inflammatory bowel disease drug previously sold by VivoSim. The company remains eligible for up to $45 million in additional milestones if specified regulatory and commercial goals are achieved as Eli Lilly advances and markets the drug.
VivoSim also issued FY2027 guidance, stating it anticipates over 500% revenue growth, driven by increasing adoption of its NAMkind 3D human cellular models in contract research by pharmaceutical customers. The company highlighted liver and intestine models with reported predictive accuracies around 90%+, aligning with FDA encouragement of human-relevant NAMs.
Positive
- $5 million milestone payment received from Eli Lilly tied to Phase 2 dosing
- Eligibility for up to $45 million additional development and commercial milestones
- FY2027 guidance for 500%+ revenue growth driven by NAMs contract research uptake
Negative
- None.
News Explained
VivoSim receives cash now but no longer controls the drug program; future milestone value depends on Lilly reaching later goals.
Because the drug was sold outright, Eli Lilly controls its development; VivoSim has received the stated
Against the latest reported liquidity baseline, VivoSim had
Sources and calculations
- VivoSim July 15 milestone and guidance release (2026-07-15)
- VivoSim latest-quarter fundamentals (2026Q3)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $4,288,000 / ($2,271,000 / 90) = [object Object]
News Market Reaction – VIVS
On the day this news was published, VIVS gained 2.17%, reflecting a moderate positive market reaction. Argus tracked a peak move of +349.8% during that session. Argus tracked a trough of -30.2% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $63K to the company's valuation, bringing the market cap to $2.98M at that time. Trading volume was exceptionally heavy at 22.4x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | clinical data update | Positive | +2.9% | Presented data showing NAM liver platform superiority at ESTIV 2026 meeting. |
| Apr 28 | AI platform update | Positive | -0.7% | Announced AI tool predicting GI toxicity with 96% accuracy from intestinal models. |
| Apr 01 | public offering | Negative | +13.3% | Priced up to $4M best-efforts equity offering with associated warrants. |
| Mar 24 | ADC toxicity data | Positive | -2.4% | Reported NAM models validated for predicting antibody-drug conjugate toxicity. |
| Mar 03 | leadership change | Positive | -12.7% | Appointed new Vice President of Global Sales to drive commercial expansion. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VivoSim news, often positive in tone, has more frequently seen share-price moves that diverge from the apparent sentiment than align with it.
Key Terms
milestone payment financial
phase 2 medical
antibody drug conjugates medical
sirna medical
food and drug administration (fda) regulatory
thiazolidinediones (tzds) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a
In association with its former inflammatory bowel disease drug program developed previously and sold outright to Eli Lilly, VivoSim has received
VivoSim further announced that it anticipates significant revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to pharmaceutical companies. The company anticipates over
VivoSim’s superior results are achieved by a combination of the best biological model with the most representative primary human cell types, leveraging multiple endpoints as readouts for best prediction, and training AI prediction models with multiple endpoints that provide a rich data set, yielding high prediction accuracy. In addition to testing traditional small molecules, VivoSim is establishing competitive advantages across new biotech modalities such as antibody drug conjugates, antibodies, siRNA, and gene therapies. Many therapies still fail in human trials, most often on safety or efficacy. VivoSim’s mission is to close gaps in the ability to predict outcomes before a drug enters expensive clinical trials.
In recent months, VivoSim has demonstrated that its NAMkind™ Liver spheroid model achieved a predictive accuracy of
The United States Food and Drug Administration (FDA) is actively encouraging human-relevant NAMs in place of animal studies, a push that is resulting in greater pharma demand for new technologies. After presenting its April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the FDA recently reported that it is meeting its goals for stimulating pharma uptake of these new models. VivoSim’s novel models offer perhaps the most predictive tool to make FDA’s vision a reality.
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding NAMkind™, including target turnaround time and its potential to help users de-risk their pipelines, avoid costly downstream failures, reduce rework, prioritize the right assets, move faster, save millions and reduce risk; VivoSim’s commercial presence across Asia-Pacific; the evaluation and acceptance of scientifically robust NAM-based evidence; the Company’s ability to capture growing demand in the in vitro toxicology testing market; demand for human-relevant toxicology; the market opportunity and market size of gastrointestinal in vitro models and toxicology services; and the Company’s scaling capacity to support expanding global demand and development needs. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
